2. Metabolic Enzyme/Protease
  3. PCSK9
  4. Alirocumab

Alirocumab  (Synonyms: REGN 727; SAR 236553)

Cat. No.: HY-P9928 Purity: 97.00%
SDS COA

Molarity Calculator

Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of PCSK9. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia.

For research use only. We do not sell to patients.

CAS No. : 1245916-14-6

Size Price Stock Quantity
1 mg USD 450 In-stock
5 mg USD 1100 In-stock
10 mg USD 1750 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Alirocumab:

Alirocumab Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Alirocumab

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of PCSK9. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia[1][2][3][4][5].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Human
In Vitro

Alirocumab (0.01, 0.1, 1, 2 and 10 μM, 24-72 h) does not affect cell viability and function in hiPSC-CMs and hESC-CMs, and can be used to evaluate drug safety in lipid-lowering cardiovascular cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Alirocumab Related Antibodies

Cell Viability Assay[3]

Cell Line: hiPSC-CMs, hESC-CMs
Concentration: 0.01, 0.1, 1, 2, 10 μM
Incubation Time: 24-72 h
Result: Exhibited normal cell viability and did not affect the level of LDH release.
In Vivo

Alirocumab (3 or 10 mg/kg, subcutaneous injection weekly for 18 weeks) inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[4].
Alirocumab (10 mg/kg, intraperitoneal injection at day 0, 10, 20) inhibits PCSK9 in rats and improves systemic oxidative stress and hyperlipidemia in BDL-induced cirrhosis rats[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CETP mice model[4]
Dosage: 3 or 10 mg/kg
Administration: s.c.
Result: Decreased total cholesterol dose-dependently.
Increased hepatic LDL receptor protein levels but did not affect hepatic cholesterol and TG content.
Decreased atherosclerotic lesion size and improved plaque morphology.
Animal Model: Rat model (240-280 g) [5]
Dosage: 10 mg/kg
Administration: i.p.
Result: Elevated ammonia, total cholesterol, LDL and ox-LDL levels.
Decreased plasma levels of total cholesterol, LDL, and oxidative stress markers.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

OC(CO)COP(O)(O)=O.[Na].[Na]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Purity & Documentation

Purity: 97.00%

SDS (251 KB)

COA (231 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Alirocumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Alirocumab1245916-14-6REGN 727 SAR 236553REGN727REGN-727SAR236553SAR 236553SAR-236553PCSK9Proprotein convertase subtilisin/kexin type 9PraluentInhibitorhiPSC-CMshESC-CMsLDLCETP mice modelAnti-inflammatoryinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Alirocumab
Cat. No.:
HY-P9928
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.